What the FDA labels say about taking them together
Phenobarbital and ticagrelor
Ticagrelor's FDA label of May 7, 2026 names phenobarbital in its drug interactions section; the phenobarbital labels PlainMeds reads (2) do not name ticagrelor. The ticagrelor label: “Avoid use with strong inducers of CYP3A.”
Check it at the source: the phenobarbital FDA label on DailyMed (effective August 27, 2026); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).
What does the phenobarbital label say about ticagrelor?
Phenobarbital's label (effective August 27, 2026) and its 1 other brand-application label do not name ticagrelor in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Phenobarbital), Chartwell RX, LLC, effective August 27, 2026 (SPL set 74428144-fb24-40a5-a670-3b876e2d116c), via openFDA; the full label on DailyMed
What does the ticagrelor label say about phenobarbital?
Ticagrelor label, drug interactionsAvoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Phenobarbital | Ticagrelor | |
|---|---|---|
| Labeled for | Seizures and epilepsy | Heart attack and coronary artery disease, Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.213 per tablet 100 mg tablet | $0.253 per tablet 90 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once